07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Claudin 1 (CLDN1)

Infectious disease INDICATION: Hepatitis C virus (HCV) Mouse studies suggest anti- CLDN1 antibodies could help treat chronic HCV infection. In a humanized mouse model of HCV infection challenged with multiple HCV genotypes, pretreatment with a...
08:00 , Nov 7, 2011 |  BioCentury  |  Finance

Verastem very aggressive

Verastem Inc. is looking to be the first U.S.-based preclinical therapeutics company to go public in the last four years. The cancer stem cell company filed last week to raise up to $50 million in...
07:00 , Aug 15, 2011 |  BioCentury  |  Emerging Company Profile

Verastem: Cancer stem cell engine

Cancer stem cells have long been recognized as important therapeutic targets, but growing enough of them to allow for screening with typical drug discovery methods has been a challenge. Verastem Inc. believes its techniques have...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Immunocompetent, humanized mouse model for HCV infection An immunocompetent, humanized mouse model of HCV could help evaluate potential HCV entry inhibitors...
07:00 , Jun 16, 2011 |  BC Innovations  |  Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...
07:00 , May 12, 2011 |  BC Innovations  |  Cover Story

Making the most of the host

Although recent attention in the HCV space has focused on positive FDA panel recommendations for the protease inhibitors telaprevir and Victrelis boceprevir from Vertex Pharmaceuticals Inc. and Merck & Co. Inc. , respectively, 1 a...